I'm guessing a lot of people saw this already, but I'll post it anyway. It does not look like a silver bullet, but I guess it's better than nothing.\n\nFDA Authorizes [on an emergency basis] Monoclonal Antibody for Treatment of COVID-19\n\n>>>While the safety and effectiveness of this investigational therapy continues to be evaluated, bamlanivimab was shown in clinical trials to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo. . . . the most important evidence that bamlanivimab may be effective came from the predefined secondary endpoint of COVID-19-related hospitalizations or emergency room visits within 28 days after treatment. For patients at high risk for disease progression, hospitalizations and emergency room visits occurred in 3% of bamlanivimab-treated patients on average compared to 10% in placebo-treated patients. The effects on viral load and on reduction in hospitalizations and ER visits, and on safety, were similar in patients receiving any of the three bamlanivimab doses.<<<\n\nhttps:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19\n\n\nThe problem is that it is hard to produce and is costly, $1,500 a dose. So far only 10 million doses have been produced. It has to be given to early cases and does prevent 70% of people needing hospital. The UK in hospital trials were stopped due to lack of benefit. This probably explains why the convalescent plasma trials have shown such poor results in the hospital.